EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieRandomisierte kontrollierte Studie

Pilot study of a CCK B antagonist in patients with panic disorder: Preliminary findings

J J Sramek, M S Kramer, S A Reines, N R Cutler

Anxiety · 1994-01 · 1 (3) · 141-143

DOI: 10.1002/anxi.3070010308 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Anxiety, online erschienen am 07.11.2013. Verfasst von J J Sramek und 3 weiteren Autor:innen. Beteiligte Einrichtung: California Clinical Trials, Beverly Hills 90211, USA. Hauptthemen laut MEDLINE: Phenylurea Compounds. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L‐365,260 is a CCK B antagonist which has been shown to completely prevent CCK‐4‐induced symptoms of panic attack in single‐dose (50 mg) placebo‐controlled studies in patients with panic disorder. The present report is data from one site (n = 38) in a multicenter study (n = 88) designed to assess the preliminary efficacy and safely of L‐365,260 in patients meeting DSM‐III‐R criteria for panic disorder, with or without agoraphobia. In order to participate, male and female patients were between 18–55 years of age and in good physical health. Following a one‐week single‐blind placebo lead‐in, patients were randomized to 30 mg four times daily of L‐365,260 (n = 18; 7 M, 11 F) or placebo (n = 20; 9 M, 11 F) for six weeks. At end of study, none of the efficacy measures, including the frequency of panic attacks, the Physician's Global Improvement Scale, and the Hamilton Rating Scale for Anxiety, were significantly improved over baseline values. L‐365,260 was well‐tolerated the most common drug‐related adverse events were headache and lightheadedness. Further testing of L‐365,260 at higher dosages, or testing of other CCK B antagonists, is required to rule out the usefulness of this novel treatment approach. Anxiety 1:141–143 (1994/1995). © 1995 Wiley‐Liss, Inc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsAdolescentAdultAnti-Anxiety AgentsBenzodiazepinonesFemaleHumansMaleMiddle AgedPanic DisorderPersonality InventoryPsychometricsReceptor, Cholecystokinin BReceptors, CholecystokininTreatment Outcome

Substanzen

Anti-Anxiety AgentsBenzodiazepinonesPhenylurea CompoundsReceptor, Cholecystokinin BReceptors, CholecystokininL 365260

Autor:innen und Institutionen

  • California Clinical Trials, Beverly Hills 90211, USA.

Zitieren

APA

Sramek, J. J., Kramer, M. S., Reines, S. A., & Cutler, N. R. (1994). Pilot study of a CCK B antagonist in patients with panic disorder: Preliminary findings. Anxiety, 1(3), 141-143. https://doi.org/10.1002/anxi.3070010308

Vancouver

Sramek JJ, Kramer MS, Reines SA, Cutler NR. Pilot study of a CCK B antagonist in patients with panic disorder: Preliminary findings. Anxiety. 1994;1(3):141-143. doi:10.1002/anxi.3070010308

BibTeX
@article{Sramek1994,
  author = {Sramek, J J and Kramer, M S and Reines, S A and Cutler, N R},
  title = {Pilot study of a CCK B antagonist in patients with panic disorder: Preliminary findings},
  journal = {Anxiety},
  year = {1994},
  volume = {1},
  number = {3},
  pages = {141--143},
  doi = {10.1002/anxi.3070010308}
}
Kostenlos starten →